ATEMPT
ATEMPT tested whether a year of the antibody-drug conjugate T-DM1 could replace chemotherapy plus trastuzumab for the smallest HER2-positive breast cancers; almost no one relapsed on T-DM1, but it was not less toxic overall, so it is an alternative rather than a replacement.
Overview
The APT trial had shown that paclitaxel plus trastuzumab cures almost all node-negative HER2-positive tumours of 3 cm or less. ATEMPT randomised 497 patients with stage I HER2-positive breast cancer three to one to 17 cycles of trastuzumab emtansine or to the APT regimen. The co-primary endpoints were invasive disease-free survival with T-DM1 and a comparison of clinically relevant toxicities.
Three-year invasive disease-free survival with T-DM1 was very high, but the rate of clinically relevant toxicity was similar in the two arms, so the toxicity endpoint was not met; T-DM1 caused more thrombocytopenia and liver enzyme rises, paclitaxel more neuropathy and alopecia. T-DM1 is now listed as an alternative adjuvant option for stage I disease, especially for patients who wish to avoid chemotherapy side effects.
Similar pages
not linked directly; found by shared links- TrialNeoSphere
Shares Early HER2-positive breast cancer, Roche / Genentech, Trastuzumab, HER2-positive breast cancer and the tag subtype-trials.
- TrialGATSBY
Shares Trastuzumab emtansine, Roche / Genentech, Paclitaxel / nab-paclitaxel and the tag subtype-trials.
- TrialPATINA
Shares Breast cancer (all types), Trastuzumab, HER2-positive breast cancer and the tag subtype-trials.
- TrialGeparSixto
Shares Breast cancer (all types), Trastuzumab, Paclitaxel / nab-paclitaxel and the tag subtype-trials.
- TrialTUXEDO-1
Shares Breast cancer (all types), HER2-positive breast cancer and the tag subtype-trials.
- TrialHERACLES
Shares Trastuzumab emtansine, Trastuzumab and the tag subtype-trials.
- TrialNALA
Shares Breast cancer (all types), HER2-positive breast cancer and the tag subtype-trials.
- TrialTAM-01
Shares Breast cancer (all types) and the tag subtype-trials.